Cocrystal reports SVR12 rate of 67% for CC-31244 regimen

Cocrystal Pharma Inc. (NASDAQ:COCP) reported preliminary data from an open-label, U.S. Phase IIa trial showing that eight of 12 (67%) evaluable patients with treatment-naïve HCV genotype 1 infection who received 400 mg oral CC-31244 plus Epclusa sofosbuvir/velpatasvir for two weeks followed by Epclusa alone for four weeks achieved a sustained virologic response (SVR) 12 weeks after the end of treatment. CC-31244 is a pan-genotypic nonstructural protein 5B (NS5B) non-nucleoside inhibitor (NNI)...